

Overview of Chemical and Pharmaceutical Industry

WIRC - ICAI December 21st 2019

Rajendra Gogri

Chairman & MD, Aarti Industries Limited

AARTI INDUSTRIES LIMITED may, from time to time, make written and oral forward looking statements, in addition to statements contained in the company's filings with BSE Limited [BSE] and National Stock Exchange of India Limited [NSE], and our reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the AARTI INDUSTRIES LIMITED.

All information contained in this presentation has been prepared solely by AARTI INDUSTRIES LIMITED. AARTI INDUSTRIES LIMITED does not accept any liability whatsoever for any loss, howsoever, arising from any use or reliance on this presentation or its contents or otherwise arising in connection therewith.





01 Global Chemical Industry & its Easternization

02 Indian Pharmaceutical Industry & Contrast with Chemicals









Indian Pharmaceutical Industry & Contrast with Chemicals




About Aarti Industries..

Chemical industry, the industry of industries, differs from others along 3 main dimensions..



Only Specifications matter

- Unlike other manufacturing industries like automotive, textiles, construction etc., the products of the chemical industry are sold purely on specifications
- Brand value is not important and hence, cost leadership becomes very important
- Qualification cycle is long and supply reliability of in-spec, quality approved material is important



Chemistry more important than machines

- Chemistry/ Route of synthesis is more important than machines
- Each chemistry requires a different combination of machines, reduces flexibility vs. other industries

Inherent focus on Sustainability

- Safety, Health & Environment
 (SH&E) very important
- Inherently hazardous nature of most raw materials, products
- Intensive process conditions pressure, temperature, energy exchange etc.

The chemical industry underpins virtually every sector of the economy



$\dot{\gamma}$	80,000	Products are commercially manufactured across the chemical industry	Agrochemicals
		,	Polymers
	\$5 tn	Of Chemical Sales were recorded globally in 2018	Colors & Cosmetics
கு	4.1%	Is spent on R&D globally by the chemical industry ¹	Construction
			Surfactants
	\$92 bn	Total Trade in chemicals by India in 2018 (\$37 bn exports and \$55 bn imports)	Personal Care
ĨĨ	¢450 km	Will be invested in capacity addition and	Synthetic Materials
	\$450 bn	upgradation in the chemical industry	Water Treatment
1. Does not in	clude healthcare	and many more	

1. Does not include healthcare

Chemicals are everywhere.. Simple chemistries of Aarti's products have a host of end uses..



In lightweight polymers of the aircraft bodies



In paints that brings colour to your life



In the medicines that keep you healthy



In printing inks that help express stories



In the Agrochemicals which help improve productivity of farms



In gasoline to improve engine performance




In perfumes and flavours that tickle your senses



In soaps and shampoos that keep you clean

The industry is huge and fragmented..





 The global chemicals market is highly fragmented


 Top 23 companies account for just 20% of global market share (\$5 Trillion)

 Asia to play a dominant role in future growth – its share of market set to rise to 62 percent by 2035

Source: Hoovers.com, Dow Chemical Company Competitive Landscape; <u>http://www.americanchemistry.com/Jobs/EconomicStatistics/Industry-Profile/Global-Business-of-Chemistry</u>; <u>http://www.rolandberger.com/press_releases/global_market_for_chemicals_will_more_than_double.html</u>; http://img.en25.com/Web/ICIS/%7Be0342ce6-588f-409c-bea6-090b40cc64ae%7D_ICB_070915_Top100.pdf

The global chemical industry has shifted to the east, with China gaining a major share in the past 3 decades





Source: ICCA Report, The Global Chemical Industry, March 2019

Indian Chemical industry has a deficit whereas the pharma industry has a net surplus..



\$ 2.4

Import

\$4.9

Others

\$ 3.3

Export

\$ 3.5



Chemicals

Import

Export

\$ 0.5

Deficit

- The trade deficit may grow from USD 18 bn to USD 43 bn by 2025
- There is an **opportunity** to produce USD 126 bn worth of chemical by 2025

-\$ 0.9

\$Bn, 2019

Deficit

The Chemicals Spectrum – From Bulk to Formulations



			2	3	4	
R&D	Process orientation Feedstock,	Bulk/basic chemicals	Intermediates	Specialties (Single molecules)	Formulations	
		 Reduce fixed costs for key processes 	 Develop complex multi-step capabilities 	 Develop molecules for desired specifications, applications 	 Develop blends for desired performance 	Product orientation
OPS	cost based portfolios Large-	 Driven by feedstock, cost advantage, global balance 	 Driven by chemistry, technology, safety expertise 	 Driven by customer applications Patent protected 	 Driven by customer applications Patent protected 	Application based portfolios
*	scale plants, utilization	 Large scale, integrated plants; Efficient design 	 Moderate scale, Ability to handle variety of reaction conditions 	 Moderate scale or multipurpose for flexibility CM, tolling prevalent 	 Multipurpose facilities for flexibility CM, tolling prevalent 	Multi- purpose plants, flexibility
SCM / Procure-	Feedstock focus	 Global supply chain integration for advantage 	 Cost effective procurement of RMs for advantage 	 Cost effective procurement of RMs for advantage 	 Channel management for advantage 	Channel manage- ment focus
Sales / Marketing	Undiffer- entiated products, cost focus	 No branding, Focus on balancing spot and contract 	 No branding; Focus on building reputation and relationships 	 Some branding; Focus on technical service 	 Branded goods; Focus on segmentation and pricing 	Branded products, technical focus

Easternization of the chemical industry led to a massive gain for China over the past few decades






- **Easternization** of manufacturing has happened over the past five decades, with manufacturing GDP of **Asia** growing sharply
- Unlike other manufacturing industries, the growth of **chemicals** manufacturing sector was largely dominated by **India** and **China**
- As with other industries, China grew massively, to now have
 >40% share in global chemicals manufacturing while India lagged behind
- Now, with the increase in labor costs in China [almost double] and environmental compliance coming at par with India and the emergence of trade war between US and China, India finds itself in a sweet spot
- We need to ensure that this **opportunity** is not wasted, like some other sectors where manufacturing moved from China to other Asian geographies [textiles, electronics etc.]


China had dramatically outpaced India in terms of chemical manufacturing over the last decade...



China's investment and R&D spend in chemicals over the last 10 years has far outpaced India and other countries




From a distant third player, China has become a global leader in the chemical industry




Chemical Market Share in 2006

Chemical Market Share in 2016



India did not match China's rapid growth in the chemical sector until 2015.

Though China and India both shared the labour cost advantage around the turn of the century, China was able to far outpace India because of policy decisions and infrastructure



 \oplus

- R&D spending in China increased to EUR 12 billion in 2016 from EUR 2 billion in 2006
 China created an R&D ecosystem where technical universities worked in coordination with the industry to reverse-engineer products and reduce production costs
 China made massive investments to expand the road and rail infrastructure across the country road connectivity increased 8x between 2000 and 2005
 Chinese State-owned enterprises dominated capacity addition in basic chemicals
 - SEZ and FDI Policy

- availability of RM feedstock drove investment in value-added products
- Chinese SEZ policy worked to attract FDI based on labor reforms and tax incentives
 - Export-oriented manufacturing enabled China to benefit from the easternization trend


However, now, Indian Chemical Industry enjoys many sweet spots not just vs. China, but also vs. the West




Over the years, India has grown a critical mass in its intermediate and specialty chemicals sectors



Global multinationals need alternate sourcing destinations – other emerging countries who may have a labour cost advantage do not have an existing ecosystem in chemicals



Inherent **CAPEX** advantage: due to high proportion of structure, piping and fabrication of equipment, labor cost arbitrage is available as compared to the West, leading to CAPEX in India being 40% - 60% of the west



Additionally, demand of consumer goods in India is growing, for which chemicals industry acts as a crucial input

Above factors lead to India now being in a sweet spot of a twin pull – from China as well as from the West


Chemicals manufacturing is well placed to benefit from sector tailwinds – Global



Speciality chemicals market has been shifting eastwards with China benefitting significantly over the last 2 decades

Shift towards EM	China was the key beneficiary
Companies looking to be closer to customers	Availability of feedstock
Lower labor costs	Cheap labor and capital
Supply Chain optimizations	Sizable end use market
Strict environmental norms in western countries	Government support and ease of setting up facilities
China market	2003-08 25%
CAGR	2008-16 13%


Global Speciality chemicals market size and region-wise share



...India to benefit from China's downturn

- Gradual erosion in China's cost advantage, due to:
 - Appreciation of Chinese currency
 - o Increase in capital costs driven by adherence to stricter effluent treatment norms and environmental regulations
 - Increasing labour cost
 - Reduction of government subsidies
- Global companies trying to diversify supply risk from China which is leading to more orders for Indian chemical companies
- India is expected to benefit from this shift as there are few other countries with requisite scale, technology, raw materials, supportive government policies to capture this opportunity
- Depreciation of rupee in recent times is expected to aid the domestic • industry's export competitiveness
- Labour Costs significantly lower in India as compared to China and West.

Significant opportunity of growth for Indian speciality chemicals



Source: CRISIL Report titled "Market assessment of Speciality Chemicals"

India - Offerings & Requirements



What India offers

- Capex & Opex Cost Savings
- Availability of Feed Stock
- Skilled Manpower
- Access to Ports
- Geographic De-Risking
- Better Legal & Regulatory Framework
- Stronger IP Protection



What Indian Companies need to do

- Strong Safety, Health & Environment
- Better Project Management
- Strong R&D
- Customer Relations Management
- Operating Efficiencies
- Availability of Finance and Willingness to Invest.
- Legal & Regulatory Compliance
- Competent Manpower







01

Global Chemical Industry & its Easternization

02 Indian Pharmaceutical Industry & Contrast with Chemicals

03

About Aarti Industries..


The Pharmaceuticals industry in India



20%	share in global supply by volume	Anti Infective
		Cardiac
3 rd	Pharmaceuticals market by 2020 in terms of incremental growth	Gastro Intestinal
60 000	brands across 60 therapeutic categories and manufactures more than 500 different	Anti Diabetic
60,000	Active Pharmaceutical Ingredients (APIs)	Cancer
3000	pharma companies with a strong network of over 10,500 manufacturing facilities	Neuro
¢10 hn		Vitamins and Minerals
	India's pharmaceuticals export	Analgesics
		and many more

India Advantage Pharma





Factors influencing the Pharma industry over the last 4-5 years..










Indian Pharma has seen intense regulatory scrutiny; likely to continue owing to rigorous and holistic assessment by <u>regulators</u>

India Inspections

FDA drug-quality checks increased 18 percent in fiscal 2018 to a new peak



Source: ET analysis <u>https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/culture-of-bending-rules-in-india-challenges-u-s-drug-agency/articleshow/67769847.cms?from=mdr</u>

AARTI

INDUSTRIES

Indian Chemical Companies have grown their sales and market cap tremendously over the last 5 years..



Company	FY 2019 Rev (INR cr)	PAT (INR cr)	Market Cap (INR cr)	Revenue growth (%)	PAT Growth (%)	Mcap Growth (%)
UPL	21,609	1,447	47,223	个 62%	个 27%	↑ 110%
PI Industries	2,841	410	20,411	个 46%	个 68%	↑ 70%
SRF	7,541	642	19,026	个 79%	个 68%	↑ 191%
Aarti Industries	4,548	481	13,650	个 58%	个 157%	↑ 358%
Atul	3,983	432	11,690	个 53%	个 97%	↑ 136%
Solar	1,663	191	9,625	个 64%	个 77%	个 56%
Vinati Organics	1,108	282	8,600	个 44%	↑ 144%	↑ 202%
Deepak Nitrite	1,792	138	3,711	个 35%	↑ 158%	↑ 289%
NOCIL	1,043	184	2,442	个 45%	↑ 224%	↑ 270%
Sudarshan	1,443	152	2,389	个 32%	↑ 257%	个 287%

Source: www.moneycontrol.com

On the other hand, Indian Pharma companies have shown a mixed performance due to reasons discussed earlier...



Company	FY 2019 Rev (INR cr)	PAT (INR cr)	Market Cap (INR cr)	Revenue growth (%)	PAT growth %	Mcap Growth (%)
Sun Pharma	28,868	2,666	104,023	个 29%	↓ 41%	↓ 56%
Divi's Labs	4,880	1,352	48,560	个 58%	个 57%	个 91%
Dr. Reddy's	15385	1,950	47,638	↑ 6%	↓ 18%	↓ 21%
Cipla	12,374	1,888	37,747	↑ 22%	↑ 60%	↓ 26%
Biocon	5,381	1,001	35,256	个 29%	个 90%	↑ 299%
Lupin	16,369	611	34,896	↑ 16%	↓ 75%	↓ 62%
Piramal	13,138	1,150	32,392	个 53%	↓ 57%	↑ 208%
Torrent Pharma	7,641	436	30,866	↑ 66%	↓ 42%	个 59%
Aurobindo Pharma	19,225	2,361	27,580	↑ 61%	个 50%	↑ 27%
Cadila Healthcare	6,493	1,602	26,735	个 23%	个 26%	↓ 4%

Source: www.moneycontrol.com







Global Chemical Industry & its Easternization

02


Indian Pharmaceutical Industry & Contrast with Chemicals



Aarti Industries - Company Overview


Overview

- A leading Speciality Chemicals company in Benzene based derivatives with integrated operations and high level of cost optimization
- Established by first generation technocrats in 1984
- Pharma operations spanning APIs, intermediates and Xanthene derivatives
- Strong R&D capabilities 3 R&D facilities; dedicated pool of over 170 engineers & scientists; IPRs for developing customized products.
- Plants located in western India with proximity to ports
 - 11 for Speciality chemicals; 4 for Pharma (2 USFDA and 2 WHO/GMP)
 - 2 upcoming project sites at Dahej SEZ and 4th R&D center at Navi Mumbai



Key Metrics





While our strategy has changed over the years, our values have provided us with a strong backbone for creating a world class organization



We care for our people, our customers, our suppliers, our assets and our community. Care for our people is reflected in our people policies, programs and developmental efforts

Integrity



We strive to maintain the highest ethical and moral standards. We honour our commitments towards our people, co-workers, partners, community and society

Excellence





We continuously raise the bar for our performance standards in safety, productivity and employee & customer satisfaction, We encourage innovative ideas & creativity by promoting a learning culture


Key Milestones with Adaptive Growth Strategies


	1984 - 1991	1992 - 2011	2012 - present
Growth Strategies	SSI, Licensing, import substitution	Consolidation, Scale, cost competitiveness, exports	Productivity with Sustainability
	 Commenced 1,200 TPA Unit for Nitro Chloro Benzenes (NCB) in Sarigram, Gujarat Incorporation 1986 First large scale organ plant in Vapi (4,500 Th for NCB) 	to continuous • Custom Synthesis division at Vapi received USFDA approval 2006-08 2001 • Expanded NCB and Sulphuric acid capacity • Received USFDA appro for API unit at Tarapur • Set up a large scale hydrogenation & nitration unit at Jhagadia (Hydrogen gas via pipeline)	

Financials - Consolidated











FY19 FY15 FY16 FY17 FY18 FY16 FY19 FY15 FY17 FY18 FY15 FY16 FY17 FY18 EBITDA = Profit before Tax + Interest Expense + Depreciation - Other Income; EBIT = EBITDA-Depreciation; Capital Employed = Net Worth + LT Debt+ ST debt+ current maturity of long term debt- cash; Capital Employed adj for CWIP= Capital Employed -CWIP; ROCE= EBIT/(Average of Capital employed of current & previous year); ROCE (exc CWIP) = EBIT/(Average of Capital employed adj for CWIP of current & previous year); ROE = Net Income/Average of Net Worth of current & previous year; D/E = Total Debt/ Total Equity; Net Debt/EBITDA = (Gross Debt- cash)/ EBITDA

FY19


Strategically Located Plants



Well Diversified Across Multiple Dimensions




Supplier to leading chemical companies across the globe, with largest customer contributing to less than 5% of sales



• 85% revenue in FY19 was from customers of over 5 years

...with a well diversified product portfolio, and low dependence on individual products



Products are used across different end industries and have different business cycles

Segments	End usage industries	Product cycle	FY18-23 CAGR
Agrochem	Pesticides, Insecticides, Fungicides, Herbicides, Nutrients	Agrochemical cycle	7-9%
Dyes & Pigments	Printing inks	Normal Business cycle	10-12%
Polymer and Additives	Aircrafts, Automobiles, Cruise Liners, Bullet-proof jackets, Electronic products	Normal Business cycle	7-9% 10-11%
Pharma	Intermediates used in drugs catering to anticancer, anti-asthma and anti- hypertensive drugs oncology therapies	Non cyclical	12-13%
Others	Fuel additives, Rubber chemicals		

Our strategy is "Growth with Sustainability for Sustainable Growth"..



